HeartSciences (HSCS) Change in Receivables (2022 - 2025)

HeartSciences' (HSCS) quarterly Change in Receivables came in at -$4350.0 in Q3 2025, down 200.0% on a QoQ basis from $4350.0 in Q2 2025.

HeartSciences (HSCS) Change in Receivables (2022 - 2025) Analysis & Trends

HeartSciences (HSCS) has 3 years of Change in Receivables data on file, last reported at -$4350.0 in Q3 2025.

Quarterly Change in Receivables changed N/A year-over-year to -$4350.0 in Q3 2025, while the trailing twelve-month figure through Oct 2025 was $10800.0 (changed N/A YoY) and the FY2026 annual result came in at -$4350.0, down 200.0% from the prior year.
Change in Receivables slipped to -$4350.0 in Q3 2025, from $4350.0 in the prior quarter.
In the past five years, Change in Receivables ranged from a high of $10800.0 in Q1 2024 to a low of -$4350.0 in Q3 2025.
A 3-year average of $2119.8 and a median of $1014.5 in 2022 frame the typical range for Change in Receivables.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Receivables (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn	386.00 Mn
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn	177.00 Mn
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn	287.00 Mn
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn	46.00 Mn
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn	10.20 Mn
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn	172.10 Mn
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn	79.00 Mn
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn	-
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn	-90.00 Mn
10	HeartSciences	6.54 Mn	4.84 Mn	-	-

Download Data